News coverage about Ultragenyx Pharmaceutical (NASDAQ:RARE) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.0378330437574 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Ultragenyx Pharmaceutical (RARE) opened at $47.77 on Thursday. Ultragenyx Pharmaceutical has a 52-week low of $43.14 and a 52-week high of $91.35. The stock has a market cap of $1,951.01, a PE ratio of -6.85 and a beta of 1.83.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. The business’s revenue for the quarter was up 81.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.64) earnings per share. equities research analysts forecast that Ultragenyx Pharmaceutical will post -7.31 EPS for the current year.
RARE has been the subject of a number of analyst reports. Morgan Stanley reiterated an “equal weight” rating and issued a $71.00 target price (up from $69.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, October 6th. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Robert W. Baird reduced their price objective on shares of Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating for the company in a research note on Friday, November 3rd. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $76.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Sunday, November 5th. Finally, Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $72.06.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/01/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-ultragenyx-pharmaceutical-rare-share-price.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.